AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 281 min read

Guggenheim maintains Buy rating on Eloxx Pharma, $40 price target

Guggenheim reaffirmed its Buy rating on Eloxx Pharma, setting a $40 price target, suggesting a 200% upside from the recent close. The firm cites strong clinical trial design and experienced leadership as key positives for the company.

Original reporting
tradingview.com
Published Oct 28, 2026, 1:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 1:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Guggenheim maintains Buy rating on Eloxx Pharma, $40 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst note highlights trial design improvements and leadership changes, which could de‑risk the program and justify a higher valuation.

02

Market read

The new rating and target may prompt short‑term buying, especially among biotech-focused traders.

03

What to watch

Execution risk of the Phase 2 trial and regulatory timeline remain uncertain.

Relevance 7/10Novelty 6/10Timing: today

Background

Eloxx Pharma is developing exaluren for nonsense‑mutation ADPKD and recently appointed a new CMO.

Market effects

Sector

May lift sentiment in the broader biotech/clinical‑trial sector.

Regional

Limited to U.S. biotech investors.

Global

Low global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The upgrade may be premature if trial data later disappoints.

Key entities

  • company
    Eloxx Pharma

    Biotech firm developing exaluren for ADPKD.

  • analyst_firm
    Guggenheim

    Equity research firm that issued the Buy rating.

Read at source← All news

Related articles

OCT 20
$ELOXMedAI 8/10

Eloxx finalizes phase 2 trial design for rare kidney disease

Eloxx Pharmaceuticals (ELOX) finalized its Phase 2 trial design for exaluren in treating autosomal dominant polycystic kidney disease. The global trial will enroll 60 adults, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas as Chief Medical Officer. Exaluren has orphan drug designations in the U.S. and Europe.

investing.com2 min
OCT 20
$ELOXMedAI 8/10

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Eloxx Pharmaceuticals (ELOX) finalized its EXPRESS Phase 2 study design for treating nonsense-mutation ADPKD with exaluren, expecting first patient dosing in 3Q 2027 and topline data in 1H 2029. The study will enroll 60 patients, with htTKV growth as the primary endpoint. The FDA noted that a substantial htTKV effect could support Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas, M.D., as Chief Medical Officer.

prnewswire.com2 min
OCT 20
$ELOXMedAI 8/10

Eloxx Pharmaceuticals, Inc. (ELOX) Finalizes 52-Week Phase 2 ADPKD Study; Names New CMO

Eloxx Pharmaceuticals completed a 52-week Phase 2 study design for exaluren in 60 ADPKD patients, with dosing expected in 3Q 2027 and results in 1H 2029. The company also appointed T.R. Srinivas, M.D., as Chief Medical Officer. According to Eloxx, a significant and lasting effect on htTKV and supportive eGFR and safety data would be required for accelerated regulatory pathways.

tradingview.com2 min
OCT 20
$ELOXMed

A yearlong study is designed to test a potential treatment in about 60 adults with inherited kidney disease.

Eloxx Pharmaceuticals (ELOX) finalized its EXPRESS Phase 2 trial design for exaluren, a potential treatment for inherited kidney disease ADPKD. The 52-week study will enroll 60 patients, with topline data expected in 1H 2029. The FDA noted that a substantial htTKV effect could support Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas as Chief Medical Officer to lead its rare kidney programs. Exaluren has received orphan drug designations in the US and Europe.

stocktitan.net2 min